Taisho Pharmaceutical secures exclusive Japanese rights to Kaigene’s FcRn inhibitor KG006, unlocking up to $22 million in milestones
Executive summary: Kaigene granted Taisho Pharmaceutical exclusive rights to clinically develop, register and commercialize its FcRn inhibitor KG006 in Japan for a $5 million upfront fee and up to $22 million in milestones. The agreement adds a promising autoimmune candidate to Taisho’s Japanese portfolio and gives Kaigene immediate cash to support KG006’s clinical progress.
Who is involved: Kaigene (licensor), Taisho Pharmaceutical (licensee), and the asset KG006.
Likely next: Taisho will initiate Japanese clinical trials and regulatory submissions for KG006, while Kaigene may pursue additional partnerships for other territories.
On July 31 2026, Kaigene announced that Taisho Pharmaceutical has obtained an exclusive license to develop, register and commercialize KG006, a next‑generation FcRn inhibitor, in Japan. Under the agreement Kaigene receives an upfront payment of $5 million and is eligible for additional milestone payments that could total $22 million. The deal expands Taisho’s autoimmune pipeline while providing Kaigene with non‑dilutive funding to advance the asset through clinical development.
Timeline
- — Kaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan (PR Newswire)